Mindleap Health

Mindleap Health is a Vancouver-based neurotechnology and digital health company operating at the intersection of mental health care and psychedelic medicine. The company has developed a mobile platform that connects patients with licensed mental health practitioners to provide structured support before and after psychedelic-assisted therapy sessions. Their core product is designed to extend and reinforce the therapeutic benefits of psychedelic treatments by ensuring patients receive guided integration care, a critical but historically underserved component of the treatment journey. By digitizing this support layer, Mindleap creates a scalable infrastructure for a category of care that has traditionally relied on fragmented, in-person resources.

Mindleap Health has secured seed funding of five million dollars, positioning the company among an emerging cohort of early-stage ventures working to build the digital backbone of the psychedelic medicine industry. Their platform addresses a growing clinical need as regulatory momentum around psychedelic-assisted therapies continues to build in North America, particularly in Canada, where the therapeutic use of substances like psilocybin and MDMA has seen meaningful policy progress. By establishing early infrastructure in the integration care space, Mindleap is developing a market position that could prove strategically valuable as clinical adoption of psychedelic therapies scales. The company's Vancouver base also places it within one of the most progressive regulatory environments in North America for psychedelic medicine development.

Mindleap Health represents an important development for the neurotechnology industry because it tackles the durability problem that has long complicated the translation of psychedelic research into lasting clinical outcomes. Neuroscience research increasingly supports the idea that the integration period following a psychedelic experience is as therapeutically significant as the session itself, making Mindleap's platform scientifically grounded and clinically relevant. Their work helps bridge the gap between acute neuroplasticity windows opened by psychedelic compounds and the sustained behavioral and psychological changes that define meaningful treatment success. As the broader neurotech sector looks to combine pharmacological, biological, and digital tools to address mental health at scale, companies like Mindleap are helping to define what comprehensive, technology-enabled care in this space can look like.